超越指南推荐:痛风降尿酸治疗的策略探讨
本文综述了痛风降尿酸治疗中「达标治疗(treat-to-target血清尿酸)」策略的推荐背景,并探讨了「避免症状治疗(treat-to-avoid-symptoms)」策略的可能定义及实施难点,指出缺乏统一定义阻碍了两种策略长期管理的临床试验设计。
要点
- 多数风湿病学会多年来推荐降尿酸治疗采用「达标治疗血清尿酸」策略。
- 「避免症状治疗」策略被提出但缺乏明确定义及临床试验实施方法。
- 定义不清阻碍了比较两种策略的长期痛风管理临床试验设计。
核心结论
- 本文讨论达标治疗尿酸策略的依据及避免症状策略的可能定义,并提出解决不确定性的方法。
研究设计与样本
- 综述,检索范围原文未报告。
主要发现
- 多数风湿病学会多年来推荐降尿酸治疗采用「达标治疗血清尿酸」策略。
- 「避免症状治疗」策略被提出但缺乏明确定义及临床试验实施方法。
- 定义不清阻碍了比较两种策略的长期痛风管理临床试验设计。
关键数值与推荐
- 原文未报告具体标准与数值。
临床怎么用
- 原文未据此给出推荐。
局限性
- 「避免症状治疗」策略缺乏明确定义及临床试验实施方法。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The 'treat-to target serum urate strategy' when using urate-lowering therapy has been recommended by most specialist rheumatology societies for many years. An alternative "treat-to-avoid-symptoms" in gout has been suggested, albeit without a clear definition of what this means and how it might be implemented in clinical trials or clinical practice. This has hampered efforts to design clinical trials that compare the "treat-to-target [urate]" and "treat-to-avoid-symptoms" strategies in the long-term management of gout. In this review we consider the rationale for the treat-to-target urate strategy when using urate-lowering therapy, potential definitions of a "treat-to-avoid-symptoms" strategy, or perhaps what is not "treat-to-avoid-symptoms", and approaches that might address this uncertainty.
引用
- Stamp LK, Dalbeth N. Moving urate-lowering therapy in gout beyond guideline recommendations. Semin Arthritis Rheum. 2024. PMID: 38219395. doi:10.1016/j.semarthrit.2023.152358
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。